Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna(Ontario Institute for Cancer Research), Paul A. Bunn(University of Colorado Denver), Miklos Pless(Ontario Institute for Cancer Research), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Christopher E. Desch(American Society of Clinical Oncology), U. Gatzemeier(Ontario Institute for Cancer Research), Thomas Müller(Johns Hopkins University), Shaharyar, Frances A. Shepherd(University Health Network), Radj Gervais(Centre François Baclesse), Thomas Chang Yao Tsao(Ontario Institute for Cancer Research), Jose R. Pereira(Ontario Institute for Cancer Research), Lawrence Einhorn(Ontario Institute for Cancer Research), Paolo Paoletti(Heidelberg University), Klára Szondy(Ontario Institute for Cancer Research), Christian Manegold(Ontario Institute for Cancer Research), Hong-Liang Lim(Ontario Institute for Cancer Research), Filippo de Marinis(Carlo Forlanini Hospital), Sofia Paul(Ontario Institute for Cancer Research), Frank V. Fossella(Ontario Institute for Cancer Research)
Cited by 2,432
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k